249 related articles for article (PubMed ID: 18413366)
1. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway.
Cheng W; Tseng CJ; Lin TT; Cheng I; Pan HW; Hsu HC; Lee YM
Carcinogenesis; 2008 Jul; 29(7):1319-26. PubMed ID: 18413366
[TBL] [Abstract][Full Text] [Related]
2. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957
[TBL] [Abstract][Full Text] [Related]
3. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.
Li N; Wei L; Liu X; Bai H; Ye Y; Li D; Li N; Baxa U; Wang Q; Lv L; Chen Y; Feng M; Lee B; Gao W; Ho M
Hepatology; 2019 Oct; 70(4):1231-1245. PubMed ID: 30963603
[TBL] [Abstract][Full Text] [Related]
4. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway.
Tang W; Feng X; Zhang S; Ren Z; Liu Y; Yang B; lv B; Cai Y; Xia J; Ge N
Cell Physiol Biochem; 2015; 36(3):1223-36. PubMed ID: 26138883
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 induces oncogenicity by preventing IGF-1R degradation, a process that can be blocked by Grb10.
Cheng W; Huang PC; Chao HM; Jeng YM; Hsu HC; Pan HW; Hwu WL; Lee YM
Oncotarget; 2017 Oct; 8(46):80429-80442. PubMed ID: 29113314
[TBL] [Abstract][Full Text] [Related]
8. Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells.
Kwack MH; Choi BY; Sung YK
Mol Cells; 2006 Apr; 21(2):224-8. PubMed ID: 16682817
[TBL] [Abstract][Full Text] [Related]
9. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
10. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
11. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.
Sun CK; Chua MS; He J; So SK
Neoplasia; 2011 Aug; 13(8):735-47. PubMed ID: 21847365
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
[TBL] [Abstract][Full Text] [Related]
13. Serum from Chronic Hepatitis B Patients Promotes Growth and Proliferation via the IGF-II/IGF-IR/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma Cells.
Ji Y; Wang Z; Chen H; Zhang L; Zhuo F; Yang Q
Cell Physiol Biochem; 2018; 47(1):39-53. PubMed ID: 29763915
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
15. Overgrowth of a mouse model of the Simpson-Golabi-Behmel syndrome is independent of IGF signaling.
Chiao E; Fisher P; Crisponi L; Deiana M; Dragatsis I; Schlessinger D; Pilia G; Efstratiadis A
Dev Biol; 2002 Mar; 243(1):185-206. PubMed ID: 11846487
[TBL] [Abstract][Full Text] [Related]
16. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner.
Gonzalez AD; Kaya M; Shi W; Song H; Testa JR; Penn LZ; Filmus J
J Cell Biol; 1998 Jun; 141(6):1407-14. PubMed ID: 9628896
[TBL] [Abstract][Full Text] [Related]
17. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis.
Pan Z; Chen C; Long H; Lei C; Tang G; Li L; Feng J; Chen F
Mol Med Rep; 2013 Mar; 7(3):969-74. PubMed ID: 23338845
[TBL] [Abstract][Full Text] [Related]
19. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
[TBL] [Abstract][Full Text] [Related]
20. Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop.
Bie C; Chen Y; Tang H; Li Q; Zhong L; Peng X; Shi Y; Lin J; Lai J; Wu S; Tang S
Dig Dis Sci; 2022 Feb; 67(2):569-584. PubMed ID: 33559791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
